Roche’s Tecentriq Hybreza Receives the US FDA’s Approval for Cancer Treatment
Shots:
- The US FDA has approved Tecentriq Hybreza (SC) to treat all IV indications, incl. lung, liver, skin & soft tissue cancers. Regulatory reviews across other regions are underway
- The approval was supported by P-IB/III (IMscin001) study assessing Tecentriq Hybreza (SC) vs Tecentriq (IV) in locally advanced or metastatic NSCLC patients (n=371) failed on Pt therapy and P-II (IMscin002) assessing patient preference b/w SC vs IV in those (n=179) with PD-L1+ve resected Stage II-IIIB NSCLC & untreated Stage IV NSCLC
- IMscin001 trial showed consistent Tecentriq levels in blood with safety profile aligning with IV formulation. In the IMscin002 trial, 71% preferred SC over IV, with 79% opting to continue treatment with it
Ref: Roche | Image: Roche
Related News:- Roche’s Tecentriq SC Receives the EC’s Approval for Treating Various Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
